Please select the option that best describes you:
Topics:
Gastrointestinal Cancers • Medical Oncology • Colorectal Cancer • Journal Club ft. Lancet publication
What factors do you consider when deciding between dual vs single-agent immunotherapy for patients with MSI-H or dMMR metastatic CRC?
Is there any data comparing Nivo/Ipi Vs Pembro or Dostarlimab? Can this be extrapolated from the CM-8HW Nivo/Ipi vs Nivo arm?
Answer from: Medical Oncologist at Academic Institution
Given all the data we have, I am personally biased and prefer dual immunotherapy for most mCRC patients unless there is significant concern for tolerance (frail patients, limited disease burden, underlying well-controlled certain auto-immune disease, etc).
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
When making the decision between dual immune checkpoint, such as nivolumab/ipilimumab, versus monotherapy, I consider both available data as well as specific patient considerations. The first results from the nivolumab + ipilimumab versus nivolumab arms of the CheckMate 8HW trial were presented at G...